Cecile Chartier-Courtaud

This inventor holds 14 USPTO granted patents and 23 published patent applications and 2 EPO patents. Top assignees: Iovance Biotherapeutics, Inc., Oncomed Pharmaceuticals, Inc.. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Cecile Chartier-Courtaud. Retrieved from https://idiyas.com/inventor/cecile-chartier-courtaud

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 14 (Patent Applications = 23)

% Patents Active = 71.4

EPO Patents = 2 (Patent Applications = 19)

Average Co-Inventor Count = 2.4

ph-index = 4

Forward Citations = 37(Granted Patents)

Company Filing History:

10 out of 110

Iovance Biotherapeutics, Inc.

patents

4 out of 94

Oncomed Pharmaceuticals, Inc.

patents

Years Active: 2014-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12642268 - CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY (2026-06-02),

2. 12516291 - PROCESSES FOR THE PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) AND METHODS OF USING THE SAME (2026-01-06),

3. 12495791 - CLOSED PROCESS FOR EXPANSION AND GENE EDITING OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF SAME IN IMMUNOTHERAPY (2025-12-16),

4. 12343380 - Expansion of TILs utilizing AKT pathways inhibitors (2025-07-01),

5. 12104172 - Processes for generating TIL products enriched for tumor antigen-specific t-cells (2024-10-01),

6. 12031157 - Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy (2024-07-09),

7. 12024718 - Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy (2024-07-02),

8. 11866688 - Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy (2024-01-09),

9. 11713446 - Processes for generating TIL products enriched for tumor antigen-specific T-cells (2023-08-01),

10. 11384337 - Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy (2022-07-12),

11. 9644034 - Anti-RSPO2 antibodies and uses thereof (2017-05-09),

12. 9109025 - Anti-RSPO2 antibodies (2015-08-18),

13. 9109024 - Anti-RSPO1 antibodies and uses thereof (2015-08-18),

14. 8802097 - Anti-RSPO1 antibodies (2014-08-12),

Sure! Here is the article about inventor Cecile Chartier-Courtaud:

Title: Innovator Spotlight - Cecile Chartier-Courtaud: Pioneering Breakthroughs in Immunotherapy

Introduction:

Cecile Chartier-Courtaud, a talented inventor based in Palo Alto, CA, has made significant contributions to the field of immunotherapy with his innovative approach and dedication to advancing medical science.

Latest Patents:

1. "Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy": Cecile's groundbreaking invention revolutionizes the methods for expanding TILs in a closed system, leading to improved efficacy and reduced costs in immunotherapy treatments.

2. "Processes for generating TIL products enriched for tumor antigen-specific T-cells": This patent highlights Cecile's expertise in reprogramming TILs to enhance their therapeutic efficacy, making them ideal for therapeutic treatment regimens.

Career Highlights:

Having secured an impressive 7 patents, Cecile has demonstrated his prowess in the medical field. His tenure at companies such as Oncomed Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc. showcases his commitment to pushing the boundaries of medical innovation.

Collaborations:

During his career, Cecile has worked alongside esteemed colleagues such as Austin L Gurney and Fumiko Takada Axelrod. Together, they have contributed to the development of novel therapies that have the potential to improve patient outcomes and revolutionize the field of immunotherapy.

Conclusion:

Cecile Chartier-Courtaud's dedication to advancing immunotherapy through his pioneering inventions has solidified his reputation as a highly respected innovator in the medical community. His collaborative spirit and drive to find new solutions make him a leading figure in the field, shaping the future of cancer treatment.

Profile summary based on public USPTO records.